Congratulations to Karuna Therapeutics and @bmsnews on the FDA approval of Cobenfy (formerly KarXT) for the treatment of #schizophrenia in adults. We’re immensely proud to have invented the first major innovation in decades for those living with schizophrenia, and this approval underscores the success of our model and our dedication to #GivingLifeToScience https://t.co/PypizR0SfQ
Does saving lives earn you extra credit for ESG compared to a sneaker company? Not yet, but in this opinion piece, I discuss where the Wild West of ESG ratings stands & where it may evolve. @rapport_bio @kiranshaw @CT_Morrison https://t.co/NBYI40CLOG
We’re pleased to announce that the U.S. FDA has granted #OrphanDrug designation to our wholly-owned clinical therapeutic candidate, LYT-200, for the treatment of #pancreaticcancer. https://t.co/62LjpZ59v4
Saddened by the loss of our dear friend Fred Frank, a founding father of the #biotech industry & longtime senior advisor to PureTech. An early & steadfast supporter, his influence will continue to inspire & guide us in our mission of advancing scientific breakthroughs to patients
.@PureTechH rang in the new year by ringing the @Nasdaq opening bell! I'm so proud to be a part of this team as we develop medicines for devastating diseases. #BIGAxis
Today we celebrated our virtual @Nasdaq opening bell ringing. We are so proud of everything our team has accomplished together and we are committed to making a difference for patients. #BIGAxis
Our team is excited to ring the @Nasdaq Opening Bell tomorrow in a virtual ceremony alongside members of our board and some of our scientific collaborators. @kiranshaw@John_LaMattina@jonykipnis#JPM21 https://t.co/EuVljp2424
Thrilled to share #biotech entrepreneur @KiranShaw joined our board of directors. Founder of @Bioconlimited, India’s largest #biopharma company, she is one of the most influential women in business. We’re proud to have her on our board of industry leaders. https://t.co/0aL2yUe4ZK
Congrats to the @AkiliLabs team on EndeavorRx, now FDA-cleared as a digital treatment for #ADHD & now the second product developed from our R&D model to receive FDA clearance
Many of the millions infected with #COVID19 may be at risk for serious respiratory complications post recovery. We plan to advance our wholly-owned clinical candidate in a global, randomized, placebo-controlled trial https://t.co/hVaIWFYxNX
.@AkiliLabs announced that ENDEAVOR (AKL-T01) is available in the US for children w/ #ADHD under FDA’s #COVID19 Enforcement Discretion Guidance. ENDEAVOR is a first-of-its-kind, #digitalmedicine experience to help children address inattentiveness from home https://t.co/K5juoSzSnC
Congrats to our founder & CEO @daphnezohar named to @BosBizJournal’s Power 50 List of most influential leaders. This year’s #BBJPower50 includes those who are making an impact and have earned respect from coworkers & industry peers #BIGAxis#immunology https://t.co/FNXDcspNEs
We are excited to open our new HQ in the #BostonSeaport! Building on our leadership in #BIGAxis biology, our integrated office & lab space will enable the expansion of our internal R&D pipeline to address #immune, #lymphatic#CNS disorders, & #cancer. https://t.co/zVbeYKGVqX
I couldn't agree more @Khanna_S
This episode shows *exactly* WHY we need the FDA regulating #FMT. I understand why some have concerns about regulation, but it is necessary for the FDA to gather the information needed to establish the safety of FMT @phylogenomics@sheridan_kate
We're excited to share a new option for weight management: PLENITY has been cleared by the FDA for use by adults with BMIs of between 25-40 kg/m² w/diet+exercise. Important safety info: https://t.co/0lAz0rDAYl. Read more here: https://t.co/bKaOSAj3nq #obesity#weightcontrol
That’s totally not true. Drug companies employ people at all levels who care deeply about patients, many of whom entered the industry because of personal/family stories. If you want to make a difference in drug pricing (a noble goal), don’t try to make good people into villains
Our affiliate @VedantaBio today announced a new immuno-oncology collaboration with @bmsnews to evaluate novel microbiome-derived immuno-oncology candidate VE800 & Opdivo in patients w/metastatic or advanced #cancers#immunooncology#microbiome https://t.co/SnXke964Yz